ANAPTYSBIO, INC. Increase (Decrease) in Prepaid Expense and Other Assets
ANAPTYSBIO, INC. (ANAB) reported Increase (Decrease) in Prepaid Expense and Other Assets of $3.67 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-09-21
- ANAPTYSBIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $5.17M, a 2046.47% increase year-over-year.
- ANAPTYSBIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.50M.
- ANAPTYSBIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.17M, a 142.01% decline year-over-year.
- ANAPTYSBIO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$352.00K.
- ANAPTYSBIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$1.81M.
- ANAPTYSBIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$112.00K, a 102.67% decline from fiscal 2023.
- ANAPTYSBIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $4.19M, a 415.87% increase from fiscal 2022.
- ANAPTYSBIO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $813.00K, a 54.86% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.17M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $3.67M 10-KT · filed 2026-09-21 | $2.50M derived: sum of 3 quarters · filed 2026-09-21 | $2.15M derived: sum of 4 quarters · filed 2026-09-21 | ||||
| 2026-03-31 | -$1.50M 10-Q · filed 2026-05-12 | -$2.67M derived: sum of 2 quarters · filed 2026-09-21 | -$3.03M derived: sum of 3 quarters · filed 2026-09-21 | -$2.79M derived: sum of 4 quarters · filed 2026-09-21 | ||||
| 2025-12-31 | -$1.17M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$1.52M derived: sum of 2 quarters · filed 2026-09-21 | -$1.28M derived: sum of 3 quarters · filed 2026-09-21 | -$1.81M 10-KT · filed 2026-09-21 | -$1.61M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | -$352.00K derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | -$111.00K derived: sum of 2 quarters · filed 2026-09-21 | -$641.00K 10-Q · filed 2025-11-04 | $2.15M derived: sum of 4 quarters · filed 2026-09-21 | ||||
| 2025-06-30 | $241.00K derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | -$289.00K 10-KT · filed 2026-09-21 | -$944.00K 10-Q · filed 2025-08-06 | $2.50M derived: sum of 3 quarters · filed 2026-09-21 | $1.10M derived: sum of 4 quarters · filed 2026-09-21 | |||
| 2025-03-31 | -$530.00K 10-Q · filed 2026-05-12 | $2.26M derived: sum of 2 quarters · filed 2026-09-21 | $857.00K derived: sum of 3 quarters · filed 2026-09-21 | -$2.21M derived: sum of 4 quarters · filed 2026-09-21 | ||||
| 2024-12-31 | $2.79M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $1.39M derived: sum of 2 quarters · filed 2026-09-21 | -$1.68M derived: sum of 3 quarters · filed 2026-09-21 | -$112.00K 10-KT · filed 2026-09-21 | -$3.20M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | -$1.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$4.47M derived: sum of 2 quarters · filed 2025-11-04 | -$2.90M 10-Q · filed 2025-11-04 | -$5.75M derived: sum of 4 quarters · filed 2026-03-03 | ||||
| 2024-06-30 | -$3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.50M 10-Q · filed 2025-08-06 | -$4.34M derived: sum of 3 quarters · filed 2026-03-03 | $1.45M derived: sum of 4 quarters · filed 2026-03-03 | ||||
| 2024-03-31 | $1.57M 10-Q · filed 2025-05-05 | -$1.28M derived: sum of 2 quarters · filed 2026-03-03 | $4.52M derived: sum of 3 quarters · filed 2026-03-03 | $5.81M derived: sum of 4 quarters · filed 2026-03-03 | ||||
| 2023-12-31 | -$2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.95M derived: sum of 2 quarters · filed 2026-03-03 | $4.25M derived: sum of 3 quarters · filed 2026-03-03 | $4.19M 10-K · filed 2026-03-03 | ||||
| 2023-09-30 | $5.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $7.09M derived: sum of 2 quarters · filed 2024-11-05 | $7.04M 10-Q · filed 2024-11-05 | $5.33M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $1.24M 10-Q · filed 2024-08-05 | -$464.00K derived: sum of 3 quarters · filed 2025-02-27 | -$3.29M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-03-31 | -$51.00K 10-Q · filed 2024-05-09 | -$1.76M derived: sum of 2 quarters · filed 2025-02-27 | -$4.58M derived: sum of 3 quarters · filed 2025-02-27 | -$459.00K derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$4.53M derived: sum of 2 quarters · filed 2025-02-27 | -$408.00K derived: sum of 3 quarters · filed 2025-02-27 | $813.00K 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | -$2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.30M derived: sum of 2 quarters · filed 2023-11-02 | $2.52M 10-Q · filed 2023-11-02 | -$4.22M derived: sum of 4 quarters · filed 2024-03-11 | ||||
| 2022-06-30 | $4.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $5.34M 10-Q · filed 2023-08-07 | -$1.40M derived: sum of 3 quarters · filed 2024-03-11 | $3.90M derived: sum of 4 quarters · filed 2024-03-11 | ||||
| 2022-03-31 | $1.22M 10-Q · filed 2023-05-11 | -$5.52M derived: sum of 2 quarters · filed 2024-03-11 | -$213.00K derived: sum of 3 quarters · filed 2024-03-11 | $620.00K derived: sum of 4 quarters · filed 2024-03-11 | ||||
| 2021-12-31 | -$6.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$1.43M derived: sum of 2 quarters · filed 2024-03-11 | -$601.00K derived: sum of 3 quarters · filed 2024-03-11 | $1.80M 10-K · filed 2024-03-11 | ||||
| 2021-09-30 | $5.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $6.14M derived: sum of 2 quarters · filed 2022-11-08 | $8.54M 10-Q · filed 2022-11-08 | $4.01M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $833.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.23M 10-Q · filed 2022-08-08 | -$1.29M derived: sum of 3 quarters · filed 2023-03-01 | -$673.00K derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $2.40M 10-Q · filed 2022-05-04 | $2.28M 10-Q · filed 2021-05-04 | -$2.13M derived: sum of 2 quarters · filed 2023-03-01 | -$1.51M derived: sum of 3 quarters · filed 2023-03-01 | $1.59M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | -$4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$3.91M derived: sum of 2 quarters · filed 2023-03-01 | -$815.00K derived: sum of 3 quarters · filed 2023-03-01 | -$1.05M 10-K · filed 2023-03-01 | -$2.11M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $621.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.71M derived: sum of 2 quarters · filed 2021-11-04 | $3.48M 10-Q · filed 2021-11-04 | $2.90M 10-Q · filed 2020-11-04 | $2.00M derived: sum of 4 quarters · filed 2022-03-07 | |||
| 2020-06-30 | $3.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $2.86M 10-Q · filed 2021-08-09 | $2.48M 10-Q · filed 2020-08-10 | $1.38M derived: sum of 3 quarters · filed 2022-03-07 | $889.00K derived: sum of 4 quarters · filed 2022-03-07 | |||
| 2020-03-31 | -$233.00K 10-Q · filed 2021-05-04 | -$1.71M derived: sum of 2 quarters · filed 2022-03-07 | -$2.20M derived: sum of 3 quarters · filed 2022-03-07 | -$5.03M derived: sum of 4 quarters · filed 2022-03-07 | ||||
| 2019-12-31 | -$1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$1.97M derived: sum of 2 quarters · filed 2022-03-07 | -$4.79M derived: sum of 3 quarters · filed 2022-03-07 | -$3.58M 10-K · filed 2022-03-07 | -$2.18M 10-K · filed 2020-03-02 | |||
| 2019-09-30 | -$490.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$3.31M derived: sum of 2 quarters · filed 2020-11-04 | -$2.10M 10-Q · filed 2020-11-04 | -$1.93M 10-Q · filed 2019-11-08 | $1.69M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | -$2.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$1.61M 10-Q · filed 2020-08-10 | -$1.44M 10-Q · filed 2019-08-08 | $2.18M derived: sum of 3 quarters · filed 2021-02-25 | $2.39M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $1.22M 10-Q · filed 2020-05-06 | $1.21M 10-Q · filed 2019-05-07 | $5.00M derived: sum of 2 quarters · filed 2021-02-25 | $5.22M derived: sum of 3 quarters · filed 2021-02-25 | $6.79M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $3.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.00M derived: sum of 2 quarters · filed 2021-02-25 | $5.58M derived: sum of 3 quarters · filed 2021-02-25 | $5.19M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $1.79M derived: sum of 2 quarters · filed 2019-11-08 | $1.40M 10-Q · filed 2019-11-08 | $1.71M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.19M 10-Q · filed 2019-08-08 | $1.49M derived: sum of 3 quarters · filed 2020-03-02 | $581.00K derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2018-03-31 | -$388.00K 10-Q · filed 2019-05-07 | -$84.00K derived: sum of 2 quarters · filed 2020-03-02 | -$993.00K derived: sum of 3 quarters · filed 2020-03-02 | $1.35M derived: sum of 4 quarters · filed 2020-03-02 | ||||
| 2017-12-31 | $304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$605.00K derived: sum of 2 quarters · filed 2020-03-02 | $1.74M derived: sum of 3 quarters · filed 2020-03-02 | $1.89M 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | -$909.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.44M derived: sum of 2 quarters · filed 2018-11-08 | $1.58M 10-Q · filed 2018-11-08 | $2.15M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-06-30 | $2.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $2.49M 10-Q · filed 2018-08-07 | $3.06M derived: sum of 3 quarters · filed 2019-02-28 | $3.20M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-03-31 | $143.00K 10-Q · filed 2018-05-08 | $711.00K derived: sum of 2 quarters · filed 2019-02-28 | $850.00K derived: sum of 3 quarters · filed 2019-02-28 | $906.00K derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2016-12-31 | $568.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $707.00K derived: sum of 2 quarters · filed 2019-02-28 | $763.00K derived: sum of 3 quarters · filed 2019-02-28 | $1.08M 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | $139.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $195.00K derived: sum of 2 quarters · filed 2017-11-07 | $511.00K 10-Q · filed 2017-11-07 | |||||
| 2016-06-30 | $56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $372.00K 10-Q · filed 2017-08-10 | ||||||
| 2016-03-31 | $316.00K 10-Q · filed 2017-05-12 | |||||||
| 2015-12-31 | -$204.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |